Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + non-pegylated liposomal doxorubicin
- Development stage
- Unknown
- Lead developer
- Arcagy Research
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
This combination chemotherapy regimen consists of carboplatin and non-pegylated liposomal doxorubicin (Myocet®). It was specifically developed and evaluated by the ARCAGY-GINECO GROUP in the MYCA trial for the treatment of patients with platinum-sensitive recurrent ovarian cancer. Carboplatin is a platinum-based alkylating agent that forms DNA cross-links, interfering with DNA repair and synthesis. Myocet is a non-pegylated liposomal formulation of doxorubicin, an anthracycline that inhibits topoisomerase II and intercalates into DNA to induce cell death. The liposomal delivery system is designed to optimize the distribution of doxorubicin to tumor sites while minimizing toxicity to healthy tissues, particularly cardiotoxicity. This regimen was investigated as a viable alternative to the standard pegylated liposomal doxorubicin-carboplatin combination during global shortages of pegylated liposomal doxorubicin.
- Brand names
- Myocet
- Other names
- carboplatin + MyocetMyocet-Carboplatinecarboplatin and liposomal doxorubicin
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on carboplatin + non-pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + non-pegylated liposomal doxorubicin.